8-K - Ensysce Biosciences, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Ensysce Biosciences, Inc. filed a Certificate of Correction on March 18, 2026, with the State of Delaware to the Certificate of Designation of Series B Preferred Stock, correcting a scrivener’s error in Section 4(d)(ii) regarding Principal Market Regulation and the Exchange Cap. The full corrected text is provided in Exhibit 3.1.

Key Takeaways

1Filed Certificate of Correction on March 18, 2026, to fix scrivener’s error in Section 4(d)(ii) of Series B Preferred Stock Certificate of Designation.

2Corrected provision addresses Principal Market Regulation, Exchange Cap under NASDAQ Listing Rule 5635(d), and allocation rules for Holders.

Current Report Details

Event Type

Charter Amendment

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

5.03

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year On March 18, 2026, Ensysce Biosciences Inc. (the “Company”) filed with the State of Del

Charter Amendment

9.01

Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 3.1 Certificate of Correction to Certificate of Designation of Series B Preferred Stoc

Exhibits Only

Exhibits (2)

3.1

EX-3.1

8-K